Abstract | BACKGROUND: METHODS: We enrolled 1733 patients with known PUFA levels who were treated in five divisions of cardiology in a metropolitan area of Japan, including 303 patients with PMI. EPA/AA and docosahexaenoic acid (DHA) to AA level ratio (DHA/AA) in patients with and without PMI were analyzed according to presence of coronary risk factors. RESULTS: Diabetes patients with PMI had significantly lower EPA/AA and DHA/AA than diabetes patients without PMI (EPA/AA: P <0.01; DHA/AA: P =0.003), with no such differences in dyslipidemia and hypertension patients. In DM patients with high high-sensitivity C-reactive protein ( hs-CRP) levels (>0.1 mg/dL), EPA/AA was low in individuals who also had PMI, whereas DHA/AA was not (EPA/AA, with PMI: 0.43 ± 0.24; without PMI: 0.53 ± 0.30, P < 0.05). Moreover, patients on statins had significantly lower DHA/AA ratios, whereas the EPA/AA ratio did not depend on statin use. Multiple regression analysis revealed that statin use in DM patients was associated with low DHA/AA but not EPA/AA. CONCLUSION: PMI patients with DM have low EPA/AA and DHA/AA. EPA/AA and DHA/AA are differently related to hs-CRP level in DM patients with PMI. Statin use can potentially affect DHA/AA but not EPA/AA, and therefore EPA/AA ratio is a better marker of assessment for cardiovascular events.
|
Authors | Masao Takahashi, Jiro Ando, Kazunori Shimada, Yuji Nishizaki, Shigemasa Tani, Takayuki Ogawa, Masato Yamamoto, Ken Nagao, Atsushi Hirayama, Michihiro Yoshimura, Hiroyuki Daida, Ryozo Nagai, Issei Komuro |
Journal | BMC cardiovascular disorders
(BMC Cardiovasc Disord)
Vol. 17
Issue 1
Pg. 41
(01 26 2017)
ISSN: 1471-2261 [Electronic] England |
PMID | 28125968
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Chemical References |
- Biomarkers
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Inflammation Mediators
- Docosahexaenoic Acids
- Arachidonic Acid
- C-Reactive Protein
- Eicosapentaenoic Acid
|
Topics |
- Aged
- Arachidonic Acid
(blood)
- Biomarkers
(blood)
- C-Reactive Protein
(analysis)
- Cross-Sectional Studies
- Diabetes Mellitus
(blood, diagnosis, epidemiology)
- Docosahexaenoic Acids
(blood)
- Dyslipidemias
(blood, diagnosis, drug therapy, epidemiology)
- Eicosapentaenoic Acid
(blood)
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hypertension
(blood, diagnosis, epidemiology)
- Inflammation Mediators
(blood)
- Male
- Middle Aged
- Myocardial Infarction
(blood, diagnosis, epidemiology)
- Retrospective Studies
- Risk Factors
- Tokyo
(epidemiology)
|